RACK1 and kidney disorder: Current studies had found that calmidazolium, as calmodulin inhibitors, could not only affect the survival status of various immune cells (Hu et al., 2019) but also affect the inositol-1,4,5-triphosphate receptor/calcium/calmodulin pathway by mediating RACK1 and regulate the proliferation of preglomerular microvascular smooth muscle cells and mesangial cells, thus treating kidney diseases (Cheng et al., 2011).